http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9220227-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2809e1b62c4df826f72cdbb9631b60c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C259-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C259-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 |
| filingDate | 1992-05-12^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2c598f4b40f4a4c4bdf63e0c3b1e4e5 |
| publicationDate | 1992-11-26^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9220227-A1 |
| titleOfInvention | Substituted orally effective ion chelators related to deferoxamine |
| abstract | Compounds are described of general formula (I), wherein R1 is acyl of the formula -C(=O)-R5; R2, R3, R4, R6¿, R¿7 and R8 are each selected from the group consisting of hydrogen and acyl of the formula -C(=O)-R5, wherein R5 is selected from the group consisting of substituted or unsubstituted alkyls, alkenyls, cycloalkyls, arylalkylenes, alkylenecycloalkyls, alkynyls and aryls; wherein R2, R3 and R4 are selected such that at least one of R2, R3 and R4 is an acyl. When R2, R3 and R4 include one or more acyls that are not identical to the acyl of R1, these compounds of formula (I) are novel compounds. The invention also includes processes to produce the compounds of formula (I). Compounds of formula (I) complex and/or chelate tissue tri-valent ions, especially iron and aluminum (Fe?+++, Al+++¿), when administered to a human being, and are therefore useful in therapy in the treatment of diseases in which tissue ion levels in the body have increased or toxic levels. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6623721-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2266953-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2266954-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02068379-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7238339-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02068379-A2 |
| priorityDate | 1991-05-13^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 360 of 360.